Sign in to confirm you’re not a bot
This helps protect our community. Learn more

End of 2023 Update

MindBio Therapeutics
56 subscribers
<__slot-el>
<__slot-el>
173 views 1 year ago #microdosing #mentalhealth #LSD
I'm very pleased to be giving this update for MindBio Therapeutics. It certainly has been a big year for us in terms of our clinical trial development, in terms of our business development and in terms of taking the company to the next stage. We have two phase two clinical trials currently underway and we're very pleased with the progress. We have a clinical trial, a phase 2A clinical trial in patients with major depressive disorder a second phase two clinical trial, and a phase 2B clinical trial in late-stage cancer patients that are experiencing existential distress. Now these two clinical trials that are underway are very important for the company. We're looking forward to a readout in Q1 of next year in our phase 2A depression trial. If we're fortunate enough to have positive data from our phase 2A depression trial, well, that will be transformative for the company If it says that MB22001 is effective in treating depression, we’ll th …...more
...more
End of 2023 Update
6Likes
173Views
2023Dec 20
I'm very pleased to be giving this update for MindBio Therapeutics. It certainly has been a big year for us in terms of our clinical trial development, in terms of our business development and in terms of taking the company to the next stage. We have two phase two clinical trials currently underway and we're very pleased with the progress. We have a clinical trial, a phase 2A clinical trial in patients with major depressive disorder a second phase two clinical trial, and a phase 2B clinical trial in late-stage cancer patients that are experiencing existential distress. Now these two clinical trials that are underway are very important for the company. We're looking forward to a readout in Q1 of next year in our phase 2A depression trial. If we're fortunate enough to have positive data from our phase 2A depression trial, well, that will be transformative for the company If it says that MB22001 is effective in treating depression, we’ll then lead straight into a phase 2B clinical trial that is a randomized and blinded, placebo-controlled clinical trial at the high standard. If that data is positive, it is indicative that this drug works in treating depressed patients. We're very excited that we've come out of a phase one clinical trial. Ordinarily, a phase one clinical trial is to show safety and adherence to protocol. And both of those things, the safety and the adherence to protocol were exactly as expected. What we didn't expect was the substantial improvements in mood in healthy men. That was quite interesting, it was a bit of a surprise when people felt more creative, they had more energy, they felt more socially connected, and they felt happier. What was also surprising in our phase one trial is that this drug improves sleep. There've been a few other surprises along the way. We've made some genetic discoveries and certainly, all of this data is being fed into the backend in what is a big data play for the company. We're really excited about the amount of information and data that we're collecting. So I'd like to wish everyone a merry Christmas. Happy New Year. However, you choose to celebrate the end of the calendar year and stay tuned for updates in the new year. #mentalhealth #microdosing #mindbio #AlbertHofmann #LSD

Follow along using the transcript.

MindBio Therapeutics

56 subscribers